



**11 October 2021**

## ASX Announcement

### Updated Investor Presentation

MELBOURNE Australia, 11 October 2021: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to share its latest investor presentation.

In the coming week Island Pharmaceuticals management team will be participating in a non-deal roadshow in the US providing an update on the Company's progress. The presentation materials are attached.

**Approved for release to the ASX by:**

Dr Paul MacLeman  
 Executive Chairman  
 Isla Pharmaceuticals  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

For further information, please contact:

<p><b>Investors:</b>          Jane Lowe          IR Department          Mobile: +61 411 117 774  <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a></p>	<p><b>Media:</b>          Juliana Roadley          IR Department          Mobile: +61 414 889 863  <a href="mailto:juliana.roadley@irdepartment.com.au">juliana.roadley@irdepartment.com.au</a></p>
---	---

**About Island Pharmaceuticals**

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.




**ISLAND**

PHARMACEUTICALS

Antiviral therapeutics

**SOLVING URGENT  
VIRAL DISEASE  
THREATS**

(ASX: ILA)  
October 2021



# DISCLAIMER

This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Island Pharmaceuticals).

## Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

**Financial data** All dollar values are in Australian dollars (\$) or A\$ unless otherwise stated. Any financial data in this presentation is unaudited.  
**Past performance** The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's

views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

## Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

# COMPANY OVERVIEW



# ISLAND AT A GLANCE

---

**Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases**

Island Pharmaceuticals listed on the ASX following oversubscribed A\$7.5m IPO in April 2021

Island's drug repurposing strategy enables rapid and efficient development of antiviral therapies

Initial focus is on mosquito borne diseases with a Phase II lead program in Dengue fever.

# SOLVING URGENT VIRAL DISEASE THREATS

## IMF estimates global Covid cost at \$28tn in lost output

World economic outlook says 2020 impact is less than thought but there will be deep scars

## Bloomberg Covid-19 Pandemic Cost Women \$800 Billion in Income in 2020


A report by Oxfam International found that the Coronavirus pandemic had a greater economic impact for women due to over-representation in the hardest-hit industries. Oxfam America's Mara Bolis explains the findings of the report on "Quicktack Charge." (Source: Bloomberg)



## TACKLING CORONAVIRUS (COVID-19) CONTRIBUTING TO A GLOBAL EFFORT

Figure 1. Almost half of all households have suffered some form of job-related disruption

Percent of respondents reporting that either they or a member of their household have/has lost a job (including self-employment/own business), and percent reporting any form of job-related disruption in the household, since the start of the COVID-19 pandemic, 2020



**United Nations @UN**

The #coronavirus outbreak could cost the global economy up to \$2 trillion this year.

@UNCTAD is calling on governments to take urgent steps to reduce the economic impact. [bit.ly/2Q2q5zc](https://bit.ly/2Q2q5zc) #COVID19


Global GDP Growth, 1995-2020

6:02 AM · Mar 10, 2020

351 See the latest COVID-19 information on Twitter

Cost Estimates

Deaths



# DRUG REPURPOSING MARKET

---

Bringing a new medicine or vaccine to market may now cost as much as **US\$2.8 billion** on average and require between 10 and 15 years' work

The global market for drug repurposing will grow from nearly **\$24.4 billion** in 2015 to nearly **\$31.3 billion** by 2020\*

## Advantages of a drug repurposing approach for antiviral drug discovery

- Low cost and less time-consuming
- Possibility to go directly to phase II clinical trials
- Potential for combination strategies
- Formulations and manufacturing chains are already established for de-risked manufacturing

# THE BENEFITS OF DRUG REPURPOSING



**De novo Drug Discovery and Development**

- Low Success Rate
- Huge Cost and Time-consuming Development

**Drug Repurposing**

- Known Drug Safety
- Reduced Pharmacokinetic Uncertainty



# ISLA-101 REPURPOSED DRUG

DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST



**ISLA-101,  
originally a cancer  
drug**



Originally identified by Johnson & Johnson and studied as a potential chemotherapy



**Demonstrated  
as safe in humans**



Used in 45 clinical studies (including Phase II & III) demonstrating an excellent safety profile in thousands of patients including children



**Strong regulatory  
history and  
acceptance**



Multiple regulatory jurisdictions have reviewed ISLA-101 as having a well established safety profile



**Speed to market  
& early revenue  
potential**



Clearance of early phases allows many years to be saved in drug development and quick path to market



**Capitalising on  
millions spent**



Funds and time spent to date reduce risk and allow for immediate move to Phase II study

# KEY COLLABORATIONS & ALLIANCES

SUPPORTING FUTURE PIPELINE DEVELOPMENT



Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed for use against Flaviviruses



Research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy. The small molecule libraries for Drug Discovery (GRIDD) Compounds Australia facility, using highly sensitive assays.



Research collaboration agreement signed with Australia's largest drug library containing approximately four and a half thousand molecules that can be searched for drug re-purposing and pipeline development



Cooperative Research and Development Agreement (CRADA) with the US Army in preparation for Phase II clinical study for ISLA-101



Supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants



Right to reference National Cancer Institute IND for ISLA-101

# INITIAL COLLABORATION

LICENSED FOR USE AGAINST FLAVIVIRUSES AND PIPELINE EXPANSION



## Monash University

- Isla US initially licensed intellectual property (IP) created by Monash University. IP was produced as part of a research project undertaken by Monash University that led to a drug candidate, ISLA-101 for repurposing. ISLA-101 is indicated for the prevention and/or treatment of mosquito borne viruses.
- Prof. David Jans at Monash Biomedicine Discovery Institute focusses on viruses of medical significance, seeking to explore virus-human protein interactions in disease, and how this can be exploited for therapeutic intervention.
- Our expanded collaboration with Prof. David Jans underpins our pipeline development strategy to pivot quickly to develop drugs as urgent emerging viral disease issues arise again.



**Prof. David Jans**

# RECENTLY SIGNED COLLABORATION

## ACCELERATE PIPELINE DEVELOPMENT



On 23 August 2021

**Island Pharmaceuticals (ASX: ILA) announced a Anti-Viral Molecule Screening Collaboration with Griffith University.**

- The new drug research collaboration focuses on repurposing small molecules with known clinical histories as new anti-viral agents.
- Accessing the small molecule libraries at Griffith Institute for Drug Discovery (GRIDD) and Compounds Australia facility, using highly sensitive assays.
- Utilises highly sensitive screening technology to assist in accelerating drug repurposing strategies
- Enhances Island's drug development pipeline, focused on advancing preventative or therapeutic drugs for existing and emerging viral threats beyond mosquito borne viruses



**Prof. Ron Quinn**  
Griffith University



**Prof. Suresh Mahalingam**  
Health Institute Queensland (MHIQ)

# BOARD, MANAGEMENT & SCIENTIFIC BOARD

EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND COMMERCIAL TRANSACTIONS.



## MANAGEMENT TEAM & BOARD OF DIRECTORS



**Dr. Paul MacLeman**  
Executive Chair



**Dr. David Foster**  
CEO & Executive  
Director



**Dr. Anna Lavelle**  
Non-Executive  
Director



**Mr. Al Hansen**  
Non-Executive  
Director



**Dr. David Brookes**  
Non-Executive Director

## SCIENTIFIC ADVISORY BOARD



**Assoc. Prof. Leigh Farrell**



**Prof. Stephen Thomas MD**



**Dr. Simon Tucker**

# CORPORATE SNAPSHOT

## ISSUED CAPITAL

Shares issued in IPO	30,000,000
Prior Shares on issue 50,968,468	50,968,468
Total number of shares on issue	80,968,468


## MARKET CAPITALISATION

IPO price (13 <sup>th</sup> April 2021)	\$0.25
Share price (as at 30 Sept 2021)	\$0.34
Market capitalisation	\$27.5M
Cash (30 June 2021)	\$6.5M

## SIGNIFICANT SHAREHOLDERS

Dr William J Garner	21,090,605	27.13%
Mr Albert Hansen (Kesa Partners)	10,837,367	13.38%
Dr David C Foster	5,146,829	6.36%
Mr Jason A Carroll	4,050,000	5.32%

## Price ILA.ASX



(13 April 2021 - 30 Sep 2021)

# ILSA-101



# ISLA-101

BRINGING ITS PLATFORM IN A PILL TO MARKET



Island has repurposed **ISLA-101**, an antiviral oral drug to treat mosquito-borne viruses (e.g. dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program

Warming global climates are accelerating the presence of mosquito-borne viruses that can cause deaths in the US, Europe and Australia

# KEY STRENGTHS



**Initially targeting dengue diseases with unmet need**

Targeting diseases, starting with dengue fever, with a significant unmet medical need and growing economic burden



**Drug repurposing strategy**

Lead compound, ISLA-101, has been in 45 clinical trials demonstrating an excellent safety profile in thousands of patients



**Phase II ready asset**

Repurposing can save tens of millions of dollars and up to a decade of development time usually required to commercialise a new drug



**Promising results to date**

Results in aggressive animal and human cellular models of dengue fever and Zika infections as well as data in a range of other flaviviruses



**Commercial upside**

Potential 'platform in a pill' to treat tropical diseases. Approval of ISLA-101 by the US FDA could see company claim a Priority Review Voucher




**Highly experienced team**

Experienced Board, Management Team & Scientific Advisory Board with extensive expertise in drug repurposing, infectious diseases and commercial transactions

# WHY DENGUE DISEASES?

SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE



Significant unmet need (3.9 billion people at risk\*)

Increasing spread to US, EU and Australia

ISLA-101 has both therapeutic and prophylactic potential

Strong animal and human model results


First claim then spring board into other viral diseases

Priority Review Voucher eligibility

\* [http://www3.weforum.org/docs/WEF\\_The\\_Global\\_Risks\\_Report\\_2021.pdf](http://www3.weforum.org/docs/WEF_The_Global_Risks_Report_2021.pdf)

# MOSQUITO BORNE DISEASES


MORE PATIENTS, HIGH COSTS, POTENTIALLY A LIFETIME OF ISSUES FOR PATIENTS



\* [http://www3.weforum.org/docs/WEF\\_The\\_Global\\_Risks\\_Report\\_2021.pdf](http://www3.weforum.org/docs/WEF_The_Global_Risks_Report_2021.pdf)

# FLAVIVIRUSES BECOMING GLOBAL

WARMING GLOBAL CLIMATES ARE EXPANDING SPREAD BEYOND THE TROPICS\*



Flaviviruses are spreading outside the tropics:

- 1 Florida, US
  - 2 Mediterranean, EU
  - 3 QLD, Australia
- Growing issue for countries hosting US military bases
- 4 Singapore
  - 5 Saudi Arabia
  - 6 Japan
  - 7 South Korea

\* Nature Microbiology | VOL 5 | June 2020 | 796-812 | [www.nature.com/naturemicrobiology](http://www.nature.com/naturemicrobiology)

# LIMITED AVAILABLE SOLUTIONS

## HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED



**Worldwide prevalence**

Dengue fever	West Nile	Zika Virus	Yellow fever	Japanese Encephalitis
390 million	n/a	Up to 1.5 million	130,000	70,000

Deformities in babies from mothers with Zika



Viral diseases are a leading cause of hospitalisation and death



**Effective drug therapy**

No	No	No	No	No
----	----	----	----	----

Antimalarial drugs market is expected to reach US\$1B in 2026 providing guidance to potential market size\*



**Vaccine**


Limited	No	No	Limited	Limited
---------	----	----	---------	---------

Vaccine development potentially can exacerbate symptoms from infections by different strains

\* Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance, Economics of Malaria Drugs in an Age of Resistance Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs; Editors: Kenneth J. Arrow, Claire Panosian, and Hellen Gelband. Washington (DC): National Academies Press (US); 2004.

# ISLA-101 PREVENTS VIRAL REPLICATION

ISLA-101 INHIBITS PROPAGATION OF FLAVIVIRUSES\*




- To replicate, the virus needs to hijack the nucleus of the host cell
- Studies demonstrated ISLA-101 prevents this so prevents virus replication
- Same mechanism of action for a therapeutic or prophylactic – either before or after exposure to the virus

**ISLA-101 targets protection of the nucleus**

**Viral replication**

# ISLA-101 BROAD ACTIVITY EVIDENT


DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN MULTIPLE MODELS OF INFECTION



- In *in-vitro* models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity
- In animal models, ISLA-101 is protective in dengue fever and Zika
- In extremely lethal animal models, ISLA-101 was shown to prevent death in 70% of subjects
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection

# SAFETY PROFILE OF DRUG ESTABLISHED

45 HUMAN CLINICAL STUDIES OF ISLA-101 COMPLETED IN OTHER INDICATIONS



Verified as safe in humans by multiple regulators in other clinical indications

# ISLA-101 ACCELERATED TIMELINE FY22

## LEVERAGING THE ESTABLISHED SAFETY PROFILE OF ISLA-101



Millions of dollars  
and years saved

Significant near-term, value accretive news flow anticipated during  
development

<u>Completed prior to IPO</u>	<u>FY21</u>	<u>H1 FY22</u>	<u>H2 FY22</u>	<u>H1 FY23</u>
<ul style="list-style-type: none"> <li>✓ Discovery</li> </ul>	<ul style="list-style-type: none"> <li>✓ ASX IPO</li> </ul>	<ul style="list-style-type: none"> <li>Sign SUNY Clinical Trial Agreement</li> </ul>	<ul style="list-style-type: none"> <li>Open IND</li> </ul>	<ul style="list-style-type: none"> <li>Trial read out</li> </ul>
<ul style="list-style-type: none"> <li>✓ Pre-clinical testing</li> </ul>	<ul style="list-style-type: none"> <li>✓ US Patent</li> </ul>	<ul style="list-style-type: none"> <li>Engage CRO</li> </ul>	<ul style="list-style-type: none"> <li>Screening subjects for enrolment in trial</li> </ul>	<ul style="list-style-type: none"> <li>Meeting with FDA</li> </ul>
<ul style="list-style-type: none"> <li>✓ Extensive Phase I safety data held on file</li> </ul>	<ul style="list-style-type: none"> <li>✓ Australian Patent</li> </ul>	<ul style="list-style-type: none"> <li>File Investigational New Drug (IND) application</li> </ul>	<ul style="list-style-type: none"> <li>First patient in Phase II trial</li> </ul>	
<ul style="list-style-type: none"> <li>✓ ISLA-101 to move straight to Phase II trials</li> </ul>	<ul style="list-style-type: none"> <li>✓ API source secured</li> <li>✓ Walter Reed conducting control arm</li> </ul>			

# DRUG DEVELOPMENT PIPELINE

Program	Indication	Stage of Development				
		Preclinical	Phase I	Phase II	Phase III	FDA Review
ISLA-101	Dengue (PEACH)	Completed		To be initiated	Planned	Planned
	Other mosquito (or vector) borne diseases	Completed	Completed	Completed	Completed	Completed
Monash Collaboration	TBD	Completed	Completed	Completed	Completed	Completed
Griffith Collaboration	TBD	Completed	Completed	Completed	Completed	Completed

# WHAT IS A CHALLENGE STUDY?

## HUMAN CHALLENGE STUDIES HAVE CONTRIBUTED VITAL SCIENTIFIC KNOWLEDGE

- In human challenge trials, participants are intentionally challenged with an infectious disease organism.
- Challenge organism may be close to wild-type and pathogenic, adapted and/or attenuated from wild-type with less or no pathogenicity.
- Human challenge studies have been conducted over hundreds of years and have contributed vital scientific knowledge that has led to advances in the development of drugs and vaccines.
- Clinical trials are designed and conducted in a manner that minimizes risks to human subjects while maximizing the potential for benefit.

Island Pharmaceuticals will work with Walter Reed Army Medical Center on its **"virus challenge model"** - Dengue Human Infection Model (DHIM) for its Phase II clinical study for ISLA-101.



# CLINICAL DEVELOPMENT PROGRAM

INITIAL FOCUS ON BRINGING A DENGUE FEVER DRUG TO MARKET

Activities to derisk Island's Investigational New Drug (IND) application



Shortened timeframe for Phase II trials

- ✓ Agreement with the National Cancer Institute in the US to use a previously approved IND Application
- ✓ Cooperative Research and Development Agreement (CRADA) with the US Army in preparation for its Phase II clinical study for ISLA-101
- ✓ Supply agreement in place with Catalent for manufacture of Fenretinide 100 mg softgels for dengue fever trial participants
- ✓ Agreement in place with Camargo to develop a nonclinical, clinical, clinical pharmacology and biopharmaceutics strategy and program

Potential expansion to other tropical diseases (eg Zika/West Nile)

Opportunity for Priority Review Voucher as a value accretion multiplier

# PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL



“PEACH” STUDY- A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL

## Phase II trial protocol

Up to 4 cohorts/4 arms

### Inclusion

- Healthy subjects
- Age 18-45
- Willing to use contraception for the duration of the study
- Informed consent

### Exclusion

- Female: pregnant or lactating
- Prior infection with HIV, HCV, Flaviviruses
- Current, or a history of, auto-immune disease


### Primary endpoint

- Assess the prophylactic effect of ISLA 101 on fever, clinical symptoms, laboratory abnormalities and viremia after challenge with DENV-1-LVHC

### Secondary endpoints

- Characterise the clinical, immunologic and virologic responses following ISLA 101 after challenge with DENV-1-LVHC
- Assess the safety of ISLA 101 in the challenge with DENV-1-LVHC

### Administer ISLA-101 daily



The study will be run at SUNY Upstate Medical University Syracuse, New York

# PRIORITY REVIEW VOUCHER ELIGIBILITY

- ISLA-101 is eligible for Neglected Tropical Disease designation for the treatment of dengue fever
- This designation means ISLA-101 has the opportunity to be awarded a Priority Review Voucher (PRV) from the FDA if first approved for dengue fever or Zika
- A PRV grants the holder an accelerated six month review of a drug application by the FDA
- As PRVs are transferable, they are highly valuable to drug development companies with numerous precedents for sales to biotech and pharma companies

## Recent PRV acquisitions

Date	Acquired by	Value
Q3 2019	Astra Zeneca	US\$95m
Q4 2019	Confidential	US\$95m
Q1 2020	Vifor Pharma	US\$111m
Q3 2020	Merck	US\$100m
Q4 2020	Abbvie	US\$95m
Q4 2020	United Therapeutics	US\$105m
Q1 2021	Alexion	US\$100m
Q3 2021	Kedrion S.p.A	US\$105m
Q1 2022	Undisclosed	\$US105m
<b>Average</b>		<b>US\$101m</b>

# COMMERCIAL OPPORTUNITY



**Prophylactic for travelers**



**Military**



**National outbreaks**



**Government Stockpiles**



**Priority Review Voucher**



**Tropical area travellers opportunity:**

- Annual market many millions of individuals (military opportunity not included)
- Predictable outbreaks will drive sales
- Increasing numbers of countries due to global warming

**Military opportunity:**

- Isla is partnering with Army (CRADA in place) for Phase IIa clinical trial in Dengue Fever
- We will pursue a contract with the military as we get closer to approval

**Endemic area opportunity:**

- Many millions of patients in Central and South America
- Potential for sales for disease suppression and treatment during outbreaks
- Potential for endemic countries to establish and maintain drug stockpiles as happens with influenza



**ISLAND**

PHARMACEUTICALS

Antiviral therapeutics

**David Foster**  
Chief Executive Officer & Executive Director  
[david@islapharma.com](mailto:david@islapharma.com)

[www.islapharma.com](http://www.islapharma.com)  
Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia

**Island Pharmaceuticals**  
**Limited**

ACN 641 183 842

# Appendix



**ISLAND**  
PHARMACEUTICALS  
Antiviral therapeutics

# INTELLECTUAL PROPERTY

---




---

In-licensed patents	<ul style="list-style-type: none"><li>• PCT/AU2014/050017, filed 16 April 2014</li><li>• National stage applications underway/filed in Australia, Brazil, Canada, Singapore &amp; US</li><li>• Issued patents in Australia, Brazil, Singapore and US</li><li>• Potential for new patents</li></ul>
Available knowhow	<ul style="list-style-type: none"><li>• Investigator Brochure from National Cancer Institute and Walter Reed Army Research Hospital</li><li>• Right of cross reference to existing IND from NCI and Walter Reed Army Research Hospital</li><li>• Rights to Walter Reed control volunteer data</li></ul>
New IP	<ul style="list-style-type: none"><li>• Likely identify inventions to patent during clinical trials to expand Island Pharma portfolio</li></ul>
Licenses	<ul style="list-style-type: none"><li>• Monash license</li><li>• Single digit royalties, deferred milestones until Phase III</li></ul>
New leads	<ul style="list-style-type: none"><li>• Research collaboration program</li></ul>

---

# ISLA101 PROTECTS HUMAN CELL CULTURE FROM DENGUE





- In pre-clinical work, ISLA-101 has been specifically shown to suppress the ability of dengue to infect human cells
- **Potential role as both preventive and treatment, enabling multiple markets**

- Vero cells cultured in the presence of different agents and infected with Dengue Virus-2.
- Viral RNA from culture from media measured as an indication of virus titer. Fraser et al. J. Infect. Dis 2014

# PROTECTS CELLS FROM INFECTION BY MANY VIRUSES

## Proven in:

- Dengue 1
- Dengue 2
- Dengue 3
- Dengue 4
- Zika
- West Nile
- Chikungunya
- Yellow Fever




- Importantly, ISAL-101 showed very a strong dose response in decreasing viral load
- This has established commencement dosing for Phase IIa Dengue challenge trial

Wang et al BBRC 2017 and WO 2014/169355

# PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE


Isla- 101 has also been shown to be protective in animal models of both dengue and Zika Virus.



Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model).

Fraser et al. J. Infect. Dis 2014

# PROVIDES PROTECTION AGAINST INFECTION OF HUMAN CELLS




- Freshly isolated human PBMCs protected from infection with dengue 2 virus in a dose dependent fashion

Fraser et al. J. Infect. Dis 2014

# PLATFORM STRATEGY: *MULTIPLE SHOTS ON GOAL*

## TARGETS

- Tropical diseases with no existing therapies
- Prophylactic or therapeutic trial potential



# BOARD OF DIRECTORS



utics

ISLAND IS LED BY A HIGHLY CAPABLE, EXPERIENCED MANAGEMENT TEAM, BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD WITH EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND EXECUTING SUCCESSFUL COMMERCIAL TRANSACTIONS.



**Dr. Paul MacLeman**  
Executive Chair

- Decades of experience across the life sciences sector, including veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance.
- Expertise in capital raising, business development, technology commercialisation, and drug development. He has founded life sciences start-ups in the biologics area and worked in investment banking.
- Previously served as Managing Director and/or CEO of several VC funded, ASX, NASDAQ and TSX listed companies. Paul is the current Chairman of AdAlta Limited (ASX:1AD). Fellow of the Australian Institute of Company Directors.



**Dr. David Foster**  
CEO & Executive Director

- 20+ years experience in life sciences representing pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice.
- Served as intellectual property counsel at Medarex, a biotherapeutics company, acquired by Bristol-Myers Squibb.
- Co-founded Roberts Foster LLP - a tech focused law firm, BioNTX a regional life science trade association, & multiple private biotechnology companies.
- Board member of BioNTX & private biotechnology companies, and is a Member of Australian Institute of Company Directors.
- Ph.D. from The University of Texas Southwestern Medical Center & J.D. from Golden Gate University School of Law.



**Dr. Anna Lavelle**  
Non-Executive Director

- Chair of Medicines Australia; Chair Avatar Pty Ltd.; previously CEO and Executive Director of AusBiotech Ltd.; Executive at the Australian Red Cross Blood Service; NED, Hemideina Pty Ltd, Cyban Pty Ltd, Sementis Pty Ltd., Research Australia, the Agricultural Biotechnology Council of Australia and the Advisory Board for the School of Biological Sciences at Monash University.
- Chaired, or has been a member of various Federal and State government advisory committees, including National Health and Medical Research Council. PhD in Genetics from the University of Melbourne, and is a Fellow of the Australian Academy of Technological Sciences and Engineering.



**Mr. Al Hansen**  
Non-Executive Director

- Managing Partner. KESA Partners. Decades of experience in healthcare and investment, including Managing Director of Signet Healthcare Partners, serving on investee companies as Chairman, Director and Interim CEO of pharmaceutical companies and CROs.
- Substantial senior investment banking experience at firms such as Darby Overseas Investments, Dillon Read and E. F. Hutton. Former Director - Corporate Finance US Treasury, and retired Captain, U.S Army Special Forces.



**Dr. David Brookes**  
Non-Executive Director

- Extensive experience in the health and biotechnology industries, including Board positions in numerous ASX listed biotechnology companies, including as Non-Executive Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc.
- Currently Non-Executive of Chairman of Anantara Lifesciences Ltd (ASX:ANR) and of Dominion Minerals Limited (ASX:DLM formerly Factor Therapeutics ASX:FTT). Non-Executive Director of TALI Digital Limited (ASX:TD1)
- MBBS (Adelaide), Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors.

# SCIENTIFIC ADVISORY BOARD

HEAVYWEIGHT ADVISORS WITH GLOBAL PEDIGREE



**Assoc. Prof. Leigh Farrell**

- Former Vice President of Business Development at Biota Pharmaceuticals (now Vaxart)
- Extensive operational and advisory experience in antiviral drug development including for the military
- Previously Chief Operating Officer, d3 Medicine, General Manager then CEO, GeneShears Pty Ltd; Research Manager Johnson & Johnson Research Pty Ltd; Associate Director, GBS Venture Partners
- Member, the Australian Research Advisory Council and the Victorian Biotechnology Advisory Council



**Dr. Simon Tucker**

- Former Vice President of Research at Biota Pharmaceuticals (now Vaxart), where he was responsible for their entire intellectual property and research portfolio and oversaw the development of the now FDA approved influenza drug Relenza, one of only three anti-virals for influenza
- Decades of experience in pharmaceutical research and development and management as CEO of both Jumpstart Fertility Inc. and Continuum Biosciences Inc
- Previously worked at GD Searle, USA, helping make key discoveries leading to the development of a treatment for HIV infection



**Prof. Stephen Thomas MD**

- International leadership role as Lead Principal Investigator for Pfizer/BioNTech global Phase III COVID-19 vaccine trial now being deployed globally
- Prof. Thomas is a world-renowned virologist and vaccinologist and has authored numerous papers and articles on dengue fever, Zika and many other infectious diseases
- Chief, Division Of Infectious Diseases, New York Upstate Medical University; Professor of Medicine, Professor of Microbiology & Immunology, and Infectious Diseases physician-scientist from the State University of New York (SUNY), Upstate Medical University; Chief, Division of Infectious Diseases and Director, Institute for Global Health and Translational Science (IGHTS)
- Twenty years in the U.S. Army Medical Corps serving at the Walter Reed Army Institute of Research (WRAIR)



**David Foster**  
Chief Executive Officer & Executive Director  
[david@islapharma.com](mailto:david@islapharma.com)

[www.islapharma.com](http://www.islapharma.com)  
Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia  
Approved for release by Paul MacLeman

**Island Pharmaceuticals**  
**Limited**

ACN 641 183 842